MBX Biosciences, Inc. is a clinical stage biopharmaceutical company pioneering investigational Precision Endocrine Peptides (PEPs™). PEPs are designed to overcome key limitations of native peptide therapeutics to deliver superior pharmacologic properties. MBX is advancing a pipeline of PEP candidates to address the unmet needs of people with endocrine disorders. The company’s lead product candidate, MBX 2109 for the treatment of hypoparathyroidism, is currently in a Phase 1 clinical trial. Members of MBX’s leadership team have collaborated over several decades on the discovery, development, and commercialization of highly successful endocrine therapeutics including Forteo® and Humalog®. The company is supported by leading life science investors including Frazier Life Sciences, New Enterprise Associates and OrbiMed.
Location: United States, Indiana, Carmel
Employees: 11-50
Total raised: $213.1M
Founded date: 2019
Investors 4
| Date | Name | Website |
| 06.07.2021 | New Enterp... | nea.com |
| - | OrbiMed | orbimed.co... |
| - | Norwest Ve... | nvp.com |
| - | Frazier Li... | frazierls.... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 05.08.2024 | Series C | $63.5M | - |
| 14.11.2022 | Series B | $115M | - |
| 28.07.2020 | Series A | $34.6M | - |
Mentions in press and media 18
| Date | Title | Description |
| 09.08.2024 | The Week’s 10 Biggest Funding Rounds: Anduril Industries Raises Big For Defense | 7 Shares Email Facebook Twitter LinkedIn Want to keep track of the largest startup funding deals in 2024 with our curated list of $100 million-plus venture deals to U.S.-based companies? Check out The Crunchbase Megadeals Board. This is a w... |
| 06.08.2024 | MBX Biosciences Secures $63.5 Million to Propel Precision Peptide Therapies | In a significant move for the biopharmaceutical landscape, MBX Biosciences has successfully raised $63.5 million in Series C financing. This funding round, led by Deep Track Capital, signals a robust vote of confidence in the company’s inno... |
| 05.08.2024 | Fast-growing MBX Biosciences raises another $63.5 million in funding | - |
| 05.08.2024 | MBX Biosciences Raises $63.5 Million in Series C Financing to Advance Precision Endocrine Peptide™ (PEP™) Platform | Financing led by Deep Track Capital, with new investments from Driehaus Capital Management and funds and accounts advised by T. Rowe Price Associates, Inc. Proceeds to support ongoing Phase 2 clinical study of once-weekly MBX-2109 in hypopa... |
| 05.08.2024 | MBX Biosciences Raises $63.5 Million in Series C Financing to Advance Precision Endocrine Peptide™ (PEP™) Platform | Financing led by Deep Track Capital, with new investments from Driehaus Capital Management and funds and accounts advised by T. Rowe Price Associates, Inc. Proceeds to support ongoing Phase 2 clinical study of once-weekly MBX-2109 in hypopa... |
| 21.11.2022 | Digital health news, funding round up in the prior week; November 21, 2022 | DispatchHealth raised $330M; Sondermind bought True Brain; Elizabeth Holmes gets 11 years in prison Top Health News Highmark Health, Google Cloud, and League unveiled their collaboration on an interoperable, digital health platform that mak... |
| 14.11.2022 | MBX Biosciences Closes $115 Million Series B Financing to Advance Development of Endocrine Disease Programs | - |
| 14.11.2022 | MBX Biosciences Closes $115 Million Series B Financing to Advance Development of Endocrine Disease Programs | - |
| 14.11.2022 | MBX Biosciences closes on $115M in drug-development funding | - |
| 14.11.2022 | MBX Biosciences Closes $115M Series B | CARMEL, IN, MBX Biosciences, a clinical stage biopharmaceutical company, announced the closing of a $115 million Series B financing. >> Click here for more funding data on MBX Biosciences >> To export MBX Biosciences funding... |
Show more